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Brief CommunicationAMPK activation caused by reduced liver lactate
metabolism protects against hepatic steatosis in
MCT1 haploinsufﬁcient miceLionel Carneiro 1, Mohamed Asrih 2, Cendrine Repond 1, Christine Sempoux 4, Jean-Christophe Stehle 5,
Corinne Leloup 3, François R. Jornayvaz 2, Luc Pellerin 1,6,*ABSTRACT
Objective: Hepatic steatosis is the ﬁrst step leading to non-alcoholic fatty liver disease, which represents a major complication of obesity. Here,
we show that MCT1 haploinsufﬁcient mice resist to hepatic steatosis development when fed a high fat diet. They exhibit a reduced hepatic
capacity to metabolize monocarboxylates such as lactate compared to wildtype mice.
Methods: To understand how this resistance to steatosis develops, we used HFD fed wildtype mice with hepatic steatosis and MCT1 hap-
loinsufﬁcient mice to study hepatic metabolism.
Results: AMPK is constitutively activated in the liver of MCT1 haploinsufﬁcient mice, leading to an inactivation of SREBP1. Therefore, expression
of key transcription factors for lipid metabolism, such as PPARa and g, CHREB, or SREBP1 itself, as well as several enzymes including FAS and
CPT1, was not upregulated in these mice when fed a high fat diet. It is proposed that reduced hepatic lactate metabolism is responsible for the
protection against hepatic steatosis in MCT1 haploinsufﬁcient mice via a constitutive activation of AMPK and repression of several major elements
involved in hepatic lipid metabolism.
Conclusion: Our results support a role of increased lactate uptake in hepatocytes during HFD that, in turn, induce a metabolic shift stimulating
SREBP1 activity and lipid accumulation.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Obesity represents a worldwide health problem. Several studies have
highlighted the involvement of the liver in the complications linked to
obesity [1e3]. Hepatic steatosis is mainly characterized by fat accu-
mulation in liver cells. Such excessive lipid accumulation can evolve
into non-alcoholic steatohepatitis (NASH), cirrhosis, and, ﬁnally, he-
patocellular carcinoma, three distinct stages of non-alcoholic fatty liver
disease (NAFLD) [4]. Obesity is one of the most common causes of
NAFLD [5]. However, the mechanisms leading to NAFLD remain
incompletely understood even though several factors have been
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[6e9].
Animal models involving high fat diet (HFD)-induced hepatic steatosis
have been extensively used to investigate this disorder [10]. Many
studies have highlighted the role of circulating fatty acids (FA) and
triacylglycerides (TAG) that tend to accumulate in the liver when their
blood concentration increases. This accumulation alters mitochondrial
function, causing oxidative stress, lipid peroxidation, and an inﬂam-
matory response that participate to insulin resistance development
[11,12]. Once NAFLD has developed, this negative loop leads to
inﬂammation and sustained lipotoxic action, allowing the progression
to NASH, cirrhosis, and hepatic carcinoma [13]. HFD models alsoervice of Endocrinology, Diabetes and Metabolism, Centre Hospitalier Universitaire
v. Bourgogne Franche-Comté, Center for Taste and Feeding Behaviour, 21000 Dijon,
itzerland 5Mouse Pathology Facility UNIL-CHUV, 1066 Epalinges, Switzerland 6Centre
IBIO, Université de Bordeaux, Bordeaux Cedex 33760, France
Bugnon 7, 1005 Lausanne, Switzerland. Fax: þ41216925505.
drine.repond@unil.ch (C. Repond), Christine.Sempoux@chuv.ch (C. Sempoux), Jean-
Francois.Jornayvaz@hcuge.ch (F.R. Jornayvaz), luc.pellerin@unil.ch (L. Pellerin).
SteatoHepatitis; ROS, Reactive Oxygen Species; ER Stress, Endoplasmic Reticulum
ylate Transporter isoform 1; SREBP1, Sterol Regulatory Element Binding Protein 1;
rate; HGP, Hepatic Glucose Production; GIR, Glucose Infusion Rate; LDHA, Lactate
the Curve; ACC, Acetyl-CoA Carboxylase; mTOR, mammalian Target Of Rapamycin;
er 12, 2017  Available online 20 October 2017
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 1625
Brief Communicationunraveled a role of decreased fat oxidation in association with a rise in
lipogenesis. These observations clearly emphasize the importance of
lipid metabolism balance in hepatic steatosis development [14,15].
In this regard, the recent development of a mouse model hap-
loinsufﬁcient for the monocarboxylate transporter isoform 1 (MCT1)
which exhibits resistance to HFD-induced obesity and associated
NAFLD is interesting for the understanding of the pathology onset [16].
MCT1 has the broadest substrate selectivity and tissue distribution
among all members of the SLC16 protein family. MCT1 transports
short-chain monocarboxylates such as lactate, pyruvate, and ketone
bodies [17]. The role of these energy substrates and their transporters
in energy homeostasis regulation remains unclear [18]. In the MCT1
haploinsufﬁcient mouse model (MCT1þ/), a reduced upregulation of
hepatic lipogenic genes was evidenced compared to the wildtype
littermate following HFD. In particular, the expression of the sterol
regulatory element binding protein 1 (SREBP1), a key lipogenic tran-
scription factor, is lower in the liver of MCT1þ/ mice [16]. Although
this previous study revealed a central role of MCT1 in diet-induced
obesity, it did not identify the mechanisms by which the partial
MCT1 invalidation protects against NAFLD.
Recently, it was demonstrated that the fuel-sensing enzyme AMP-
activated protein kinase (AMPK) inhibits SREBP1 activity [19]. Conse-
quently, this inhibition contributes to the resistance to hepatic stea-
tosis. Moreover, AMPK is a key factor that regulates several cellular
processes including glucose uptake and lipid metabolism [20]. AMPK
is rapidly activated when the AMP/ATP ratio increases. Once activated,
AMPK promotes energy producing processes, while it inhibits energy
consuming ones such as protein or fatty acid synthesis in liver [21]. As
lactate can be used by the liver as an energy substrate, we hypoth-
esized that reduced liver MCT1 expression could promote resistance to
hepatic steatosis by altering lipid metabolism though a modulation of
AMPK activity.
2. MATERIALS AND METHODS
2.1. Animals
Experiments were performed in accordance with the Swiss animal
welfare laws under the authorization n VD 2886 from the Service de la
consommation et des affaires vétérinaires du Canton de Vaud,
Switzerland.
MCT1þ/ mice (originally generated by homologous recombination,
see [16]) were bred to produce MCT1þ/ male mice and MCT1þ/þ
male littermate controls in the animal facility of the Physiology
department at the University of Lausanne, Switzerland. Animals were
housed in a controlled environment room, with a temperature of 20e
22 C, relative moisture 50e60%, and 12 h lightedark cycle. At 8
weeks old, MCT1þ/ and MCT1þ/þ littermates received either a
standard diet (SD) (Provimi Kliba, Penthalaz, Switzerland; Cat no 3336)
or a high fat diet (HFD) (Harlan Teklad, Oxon, UK; Cat no TD.93075)
with unlimited access to food and water during 12 weeks. At the end of
the 12 weeks diet period, animals were anesthetized with an intra-
peritoneal injection of sodium pentobarbital (50 mg/kg), and tissues
were collected weighted and frozen in liquid nitrogen for further
analysis. Blood glucose, ketone bodies, and lactate were measured
from tail vein using speciﬁc apparatus (Free Style precision, Abbott,
Oxon, UK for ketone bodies and glucose; The Edge analyzer, Apex
Biotechnology Corp., Taiwan for lactate).
2.2. Total RNA isolation and real-time quantitative PCR analysis
Total RNA was extracted from frozen liver using the Prep Ease RNA/
Protein Spin Kit Affymetrix (High Wycombe, United-Kingdom) according1626 MOLECULAR METABOLISM 6 (2017) 1625e1633  2017 The Authors. Published by Eto the manufacturer’s protocol. RNA was reverse-transcribed into cDNA
with the use of Takara RT-kit (Takara Biotechnology, Saint-Germain-
en-Laye, France). The abundance of transcripts was assessed by
real-time PCR (ViiA7 Real time PCR system life Technologies, Zug,
Switzerland) with a SYBR Green detection system (Applied Biosystem,
Rotkreuz, Switzerland). Differences were calculated using the DDCt
method using the Polymerase 2 gene as housekeeping gene (Primers
used are shown in Supplementary Table 1).
2.3. Western blots
Frozen livers were homogenized in RIPA lysis buffer (Millipore, Zug,
Switzerland) with phosphatase and protease inhibitors (Pierce, Lau-
sanne, Switzerland). 30 mg of total proteins were loaded on SDS-PAGE
gels and transferred to nitrocellulose membranes. Membranes were
blocked with TBS containing 0.1% Tween 20 and 5% BSA, then
incubated overnight with primary antibodies (Supplementary Table 2).
Blots were revealed by chemiluminescence (WesternBright ECL; Witec
ag, Luzern, Switzerland) and imaged with a detection system
(Chemidoc XRSþ, Biorad, Switzerland). Densitometric analysis of
chemiluminescent signals was performed using Image lab software.
2.4. Liver lipid measurements
Liver triglycerides were extracted using the method of Bligh and Dyer
[22] and measured using a kit from BioMérieux (Genève, Switzerland)
according to the manufacturer’s instructions.
2.4.1. Liver glycogen content determination
100 mg of tissue were homogenized in citrate buffer (NaF 50 mM,
Citric acid 100 mM, pH 4.2) and centrifuged at 5000 g for 10 min at
4 C. Supernatant was removed, and 460 ml were incubated with 40 ml
of a solution of amyloglucosidase 50 U/ml (Sigma) diluted in sodium
citrate buffer, while 460 ml were incubated with 40 ml of sodium citrate
buffer only. Tubes were shaken for 30 min at 55 C. Then, 10 ml of
each sample were deposited in 96 well plates with 200 ml of a RTU
(Ready to Use) buffer (BioMérieux), incubated at room temperature for
20 min. The optical density was measured at 505 nm by spectro-
photometry. The difference between conditions with amyloglucosidase
or buffer only represents the glycogen content as mg of glucose from
glycogen hydrolysis per g of liver.
2.5. Hyperinsulinemic-euglycemic clamp
After 12 weeks of diet, mice were anesthetized with 50 mg/kg sodium
pentobarbital (i.p.). An indwelling catheter was introduced in the left
jugular vein and externalized on the back. Diet was restricted to 6 h, and
mice underwent a euglycemic clamp with a continuous infusion of
human insulin (Novorapid, Novo Nordisk) at a rate of 8 mU/kg/min.
Glucose (15%) was infused at variable rates to maintain euglycemia.
Insulin-stimulated whole-body glucose ﬂux was estimated using a
continuous infusion of [3-3H] glucose at a rate of 0.09 mCi/min
throughout the clamp procedure. Blood samples (10 ml) were collected
from the tail vein for plasma [3-3H] glucose determination at 10-min
intervals during the last 30 min. Rates of whole-body glucose disap-
pearance (Rd), Hepatic glucose production (HGP) and Glucose infusion
rate (GIR) were calculated as previously described [23]. Additional blood
samples were collected to measure plasma insulin concentrations
before and at the end of the clamp using ELISA speciﬁc kits from Merk
Millipore according to manufacturer’s instructions.
2.6. Pyruvate and lactate tolerance tests
6 h fasted mice received an intraperitoneal pyruvate (2 mg/g) or lactate
(1 mg/g) injection. Blood was collected from the tail vein at e 30, 0,lsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1: MCT1D/L mice are resistant to HFD-induced obesity and insulin resistance, accumulate less triglycerides and have a decreased glycogen liver content. (A)
Blood insulin level measured at the end of the 12 weeks HFD that induced hyperinsulinemia in MCT1þ/þ mice but not in MCT1þ/. (BeD) Hyperinsulinemic-euglycemic clamps
show insulin resistance in MCT1þ/þ mice under HFD but not in MCT1þ/. Results presented show Glucose infusion Rate (GIR) to maintain euglycemia (B), Rd represents the
glucose disappearance rate (C) and HGP represents Hepatic Glucose production (D). (E) Liver triglycerides content increased in MCT1þ/þ mice after HFD, whereas in MCT1þ/
mice it did not. (F) 12 weeks HFD induced a decrease in glycogen content in both MCT1þ/þ and MCT1þ/ mice. n ¼ 12 for each group. (GeH) Comparative histological analysis
of liver from MCT1þ/þ and MCT1þ/ mice under HFD stained with hematoxylin/eosin and examined under light microscopy at 40 magniﬁcation. Calibration bar, 100 mm. (I)
Relative quantiﬁcation of lipid droplets surface ratio compared to total surface. n ¼ 2 for each group. *represents differences due to diet, # represents differences between
genotypes during HFD. * or #: p < 0.05; ** or ##: p < 0.01.15, 30, 45, 60, 90, and 120 min for determination of glucose or lactate
levels using speciﬁc apparatus (Free Style precision, Abbott, Oxon, UK
for glucose; The Edge analyzer, Apex Biotechnology Corp., Taiwan for
lactate).
2.7. Histological analysis
Animals were anesthetized and killed by cervical dislocation. An
incision in the skin was made from the rectum to the esophagus and
the entire animal was put in a buffered formol ﬁxating solution for 24 h.
Liver was dissected, parafﬁn-embedded with a Leica ASP300S tissue
processor (Leica, Heerbrug, Switzerland), and 3 mm tissue sections
prepared with a Microm HM 335 E microtome (Thermo Scientiﬁc,
Walldorf, Germany). Each section was routinely stained with hema-
toxylin and eosin, mounted on glass slides, and examined with a Nikon
Eclipse 80i microscope (Nikon AG, Egg, Switzerland) using brightﬁeld
optics at 20 and 40 magniﬁcation. On digital images of repre-
sentative sections the surface of lipid droplets was measured and the
ratio to the total tissue surface was calculated.
2.8. Statistical analysis
Results are presented as mean  SEM. Statistical analysis was per-
formed using Prism 6.01. Normality was tested with the Kolmogorove
Smirnov test. For each experiment, a one or two-way ANOVA test was
performed. Signiﬁcant differences are indicated as * for a signiﬁcantMOLECULAR METABOLISM 6 (2017) 1625e1633  2017 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comeffect of HFD in WT and HE mice; x for a signiﬁcant effect of the
transgene under SD; and # for a signiﬁcant effect of the transgene
under HFD.
3. RESULTS
3.1. MCT1þ/ mice are protected from HFD-induced insulin
resistance
MCT1 haploinsufﬁcient (MCT1þ/) mice are resistant to the devel-
opment of obesity and the appearance of hepatic steatosis when fed a
high fat diet as well as to the development of chronic hepatic
inﬂammation as indicated by the absence of TNFa mRNA induction
under HFD (Supplementary Figure 1AeE). In addition, in accordance
with glycemia measurements (Supplementary Figure 1H), plasma in-
sulin levels were increased in MCT1þ/þ mice under HFD, but not in
MCT1þ/ mice (Figure 1A). Using a hyperinsulinemic euglycemic
clamp, insulin resistance in MCT1þ/þ mice was revealed after
12 weeks of HFD as shown by both decreased glucose infusion rate
(GIR) (Figure 1B) and decreased rate of whole-body glucose disap-
pearance (Rd) (Figure 1C). In contrast, MCT1þ/mice showed no sign
of insulin resistance based on these two parameters when fed with
either a SD or HFD (Figure 1BeC). The calculated hepatic glucose
production (HGP) during hyperinsulinemia was not altered in both
MCT1þ/þ and MCT1þ/ mice (Figure 1D).an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 1627
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accumulation
To determine how these MCT1þ/ mice resist to hepatic steatosis,
hepatic lipid content was quantiﬁed. An increased triglyceride liver
content was observed in MCT1þ/þ mice after HFD, while it was
signiﬁcantly less in MCT1þ/ mice (Figure 1E). Interestingly, liver
glycogen content was decreased after HFD in both MCT1þ/þ and
MCT1þ/ mice, suggesting similar glycogen metabolism in both
groups (Figure 1F). Histological analysis of the liver revealed an
important hepatic steatosis in MCT1þ/þ mice fed HFD while it was
strongly reduced in the liver of MCT1þ/-mice fed HFD (Figure 1GeH).
Quantitatively, lipid droplets accounted for 51% of the surface in the
liver of MCT1þ/þ mice fed HFD while it represented only 20% in the
liver of MCT1þ/ mice (Figure 1I).
3.3. MCT1þ/ mice under HFD exhibit decreased responses in
both pyruvate and lactate tolerance tests
Glucose production was assessed ﬁrst with a pyruvate tolerance test.
MCT1þ/þ mice under HFD showed a higher glucose production rate
than MCT1þ/þmice fed SD which remained elevated at the end of the
test period. In contrast, MCT1þ/ mice under HFD displayed a
transient elevation of glycemia induced by pyruvate which normalized
60 min after pyruvate injection as observed for SD fed mice as shown
by the increased area under the curve (a.u.c) (Figure 2A,B), indicating
increased liver glucose production. Since MCT1 is a lactate transporter
which could be essential for neoglucogenesis, a lactate tolerance test
was performed. This test revealed a similar response than the one with
pyruvate for MCT1þ/þmice under HFD with a long-lasting increase of
glycemia compared to SD fed mice. MCT1þ/mice under HFD did not
produce such a response upon lactate injection. Interestingly, under
SD, even MCT1þ/mice presented a lower response than MCT1þ/þ
mice (Figure 2C,D). Blood lactate levels were measured after lactate
injection. Lactate levels ﬁrst increased after infusion and then
normalized in SD fed groups but not completely in HFD fed groups.
Thus, HFD fed mice (either MCT1þ/þ or þ/) exhibited long-lasting
elevation of blood lactate levels in response to a lactate injection
(Figure 2E,F). In order to understand the cause of these anomalous
responses to pyruvate and lactate, hepatic expression of key enzymes
for their metabolism was determined. Expression of pyruvate
carboxylase (which converts pyruvate into oxaloacetate) was induced
only in HFD fed MCT1þ/þ mice (Figure 2G). Expression of the lactate
dehydrogenase isoform LDHA, which preferentially converts pyruvate
into lactate, was not altered either by the transgene nor the diet
(Figure 2H). In contrast, under HFD, MCT1þ/þ mice exhibited an in-
crease in the expression of the LDHB isoform which is preferentially
involved in the conversion of lactate into pyruvate. Interestingly, this
effect on LDHB was not detected in MCT1þ/ mice after HFD
(Figure 2I).
3.4. Mitochondrial complexes content is enhanced in MCT1þ/þ
mice but not in MCT1þ/ mice under HFD
Our aforementioned results suggest an alteration in oxidative meta-
bolism. Indeed, overexpression of LDHB could promote enhanced
pyruvate production from lactate. In turn, increased pyruvate carbox-
ylase expression suggests a higher activity of the Krebs cycle and of
oxidative phosphorylation. Expression levels of the four mitochondrial
complexes composing the respiratory chain were increased in HFD fed
MCT1þ/þmice (Figure 3AeD). Moreover, expression of ATP synthase
(or Complex V) was also increased in MCT1þ/þ mice fed a HFD,
suggesting an increased ATP production capacity (Figure 3E).1628 MOLECULAR METABOLISM 6 (2017) 1625e1633  2017 The Authors. Published by EInterestingly, MCT1þ/ mice did not undergo such modiﬁcations in
expression following HFD. However, expression of Complex IV was
higher compared to MCT1þ/þ mice under SD (Figure 3D). This result
suggests that the oxidative potential could be constitutively higher in
the MCT1þ/ mouse model under SD but not under HFD.
3.5. AMPK is constitutively activated in MCT1þ/ mice
Given that modiﬁcations in oxidative metabolism should have an
impact on ATP production, we postulated that the energy status-
sensitive enzyme AMPK could be affected. No modiﬁcation in the
phosphorylated state of AMPK was detected in MCT1þ/þ mice after
HFD (Figure 3F,K). However, a higher level of AMPK phosphorylation
was seen in MCT1þ/ mice compared to MCT1þ/þ mice under SD,
indicating a constitutively higher AMPK activity. Under HFD, this
increased activation was still present (Figure 3F,K). In accordance with
this activation, the AMPK target enzyme Acetyl-CoA Carboxylase (ACC)
was also phosphorylated and thus activated in MCT1þ/ mice,
whereas there was no signiﬁcant modiﬁcation in MCT1þ/þ mice
(Figure 3G,K). Surprisingly, mTOR (putatively in both mTORc1 and c2
complexes) and S6K, two known downstream targets of AMPK
signaling, exhibited a decreased phosphorylation ratio in MCT1þ/
mice (Figure 3H,I, and K). mTOR activation was also decreased in
MCT1þ/þ mice fed with HFD, indicating that another regulating
pathway than AMPK should be involved in mTOR signaling in this
condition. In addition, the upstream enzyme in AMPK signaling, LKB1,
known to activate AMPK, did not present any modiﬁcation of its
phosphorylation state, and thus of its activation (Figure 3J,K). Such a
result indicates that AMPK activation did not result from LKB1
signaling.
3.6. SREBP1 precursor cleavage is prevented in MCT1þ/ mice
under HFD and could protect MCT1þ/ mice against hepatic
steatosis
Recently, resistance to hepatic steatosis was associated with an in-
hibition of the production of the mature form of SREBP1 via activated
AMPK [19]. To assess this possibility, the cleaved/precursor ratio of
SREBP1 was determined by western blot. We observed an increased
ratio in HFD fed MCT1þ/þ mice due to an increased appearance of
the cleaved form (Figure 3L and M). This cleaved form did not increase
in MCT1þ/ mice either under SD or HFD condition. This suggests
that constitutively active AMPK might phosphorylate SREBP1 and
prevent its active form to be generated in MCT1þ/ mice [19].
3.7. Expression of key hepatic genes revealed a decrease in lipid
metabolism in MCT1þ/ mice
Gene expression analysis for speciﬁc proteins involved in lipid meta-
bolism such as the transcription factors PPARa and g showed a robust
increase in expression following HFD in MCT1þ/þ mice but not in
MCT1þ/ mice (Figure 4A,B). In accordance with previous studies,
HFD also enhanced the mRNA expression levels of SREBP1 and
CHREBP, both being involved in lipid and carbohydrate metabolism
(Figure 4C,D). Interestingly, SREBP1 was induced by HFD in both
MCT1þ/þ and MCT1þ/ mice. However, the expression level after
HFD was signiﬁcantly lower in MCT1þ/ mice than in MCT1þ/þ
mice (Figure 4C). Expression of Fatty Acid Synthase (FAS) was
increased in MCT1þ/þ mice following HFD but not in MCT1þ/ mice
(Figure 4E). Finally, expression of the lipid transporter CPT1 was
induced in MCT1þ/þ mice fed a HFD, indicating an increase in fat
oxidation in mitochondria, but this was not the case in HFD fed
MCT1þ/ mice (Figure 4F).lsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 2: HFD causes an increase in glucose production following pyruvate or lactate injection in MCT1D/D mice but not in MCT1D/L mice. (A) Blood glucose level
measurement following a pyruvate injection in MCT1þ/þ and MCT1þ/ mice at 12 weeks of SD or HFD and (B) Area under the curve. (C) Blood glucose level measurement
following a lactate injection in MCT1þ/þ and MCT1þ/ mice at 12 weeks of SD or HFD and (D) Area under the curve. (E) Blood lactate level measurement following a lactate
injection in MCT1þ/þ and MCT1þ/ mice at 12 weeks of SD or HFD and (F) Area under the curve. After 12 weeks of SD or HFD, liver mRNA expression levels for (G) Pyruvate
carboxylase (H) Lactate dehydrogenase A (LDH A) and (I) Lactate dehydrogenase B (LDH B) isoforms. n ¼ 12 for each group. * represents differences due to diet, # represents
differences between genotypes during HFD. * or #: p < 0.05; ** or ##: p < 0.01; *** or ###: p < 0.001.
MOLECULAR METABOLISM 6 (2017) 1625e1633  2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 3: Resistance to HFD-induced obesity in MCT1D/L mice is associated with AMPK activation independently of LKB1 activity but correlated with lower
oxidative phosphorylation capacities leading to SREBP1 inhibition. (AeE) Upper panels are representative western blots for OXPHOS complexes protein level. Lower panel
provides the quantiﬁcation of protein expression (FeJ) Ratio of phosphorylated to non-phosphorylated isoform protein for AMPK (F), ACC (G), mTOR (H), S6K (I), and LKB1 (J) and (K)
representative western blots for the same proteins and phosphorylation forms. (L) Representative western blot for precursor and cleaved forms of SREBP1. (M) Quantiﬁcation of
Cleaved to precursor SREBP1 isoforms ratio. n ¼ 7 animals per condition. *represents differences due to diet, x represents differences between genotypes during SD, and #
represents differences between genotypes during HFD. *, x or #: p < 0.05; **, xx, or ## indicates p < 0.01; ***, xxx, or ###: p < 0.001.
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Figure 4: HFD causes an increase in mRNA levels of genes involved in lipid metabolism and a metabolic shift increasing lipid metabolism in MCT1D/D but not in
MCT1D/L mice. After 12 weeks of SD or HFD, liver mRNA expression levels for transcription factors PPARa and PPARg, SREBP1, CHREB (AeD), for the enzyme involved in lipid
metabolism FAS (E) or the mitochondrial lipid transporter CPT1 (F). n ¼ 10 animals per condition. *represents differences due to diet, # represents differences between genotypes
during HFD. * or #: p < 0.05; ** or ##: p < 0.01; *** or ###: p < 0.001.4. DISCUSSION
In the present study, we report a new signaling pathway putatively
implicated in hepatic steatosis development during HFD-induced
obesity involving lactate metabolism and AMPK activity. Hepatic
steatosis is known to result from a cascade of events leading to lipid
accumulation in the liver [1,14]. High fat diet-induced obesity is
classically used as an animal model of hepatic steatosis. A recent
mouse model resistant to HFD-induced obesity and hepatic steatosis
was generated to better understand the development of such a disease
[16]. This mouse model presents the particularity to be hap-
loinsufﬁcient for the monocarboxylate transporter MCT1. Mono-
carboxylates, which include lactate, pyruvate, and ketone bodies, have
been poorly studied in the context of obesity development in the past
years. Nevertheless, different groups have highlighted a putative
implication of these substrates in metabolic control and dysregulations
but a clear role remains to be demonstrated [18].
A histological analysis (and liver TG measurements) in MCT1þ/mice
under HFD revealed a decreased lipid accumulation in the liver, sup-
porting a resistance to hepatic steatosis. This decreased lipid accu-
mulation most likely results from a decrease in lipid metabolism in this
mouse model under HFD as suggested by the reduced gene expression
of key factors involved in lipid metabolism. Usually, hepatic steatosis is
associated with insulin resistance. Here, by using the
hyperinsulinemic-euglycemic clamp technique, we demonstrated that
MCT1þ/ mice did not develop insulin resistance after 12 weeks ofMOLECULAR METABOLISM 6 (2017) 1625e1633  2017 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comHFD. However, hepatic glucose production was similar during the
clamp between groups, even in MCT1þ/þ mice under HFD, sug-
gesting that insulin resistance mainly affects other tissues than liver
such as adipose tissue and/or muscle. In our conditions, insulin
resistance did not affect hepatic glucose production but it could still
impact liver lipid metabolism [24,25].
MCT1 transports lactate, pyruvate and ketone bodies in various tissues
[17]. Ketone bodies are metabolites produced by lipid oxidation
essentially in the liver but used as energy substrates by muscles, the
heart and the brain. In contrast, lactate and pyruvate are related to
glucose metabolism and are exchanged between various organs and
tissues. It has been shown that ketone bodies are secreted by hepa-
tocytes via a different monocarboxylate transporter than MCT1 [26].
Thus, the role of MCT1 in the liver might be predominantly related to
lactate metabolism. Indeed, pyruvate injection produced a similar
response in MCT1þ/þ and MCT1þ/ mice under SD, indicating a
metabolism not affected by the haploinsufﬁciency. In contrast,
MCT1þ/ mice present a lower response to lactate for glucose
production but a normal response in terms of blood lactate. Such
results suggest that lactate metabolism per se is altered in hepato-
cytes. Interestingly, hepatocytes also express MCT2, a mono-
carboxylate transporter with a higher afﬁnity for pyruvate although it
also transports lactate [27]. We found that the expression of MCT2
mRNA is enhanced in the liver of MCT1þ/þ under HFD while this
effect was blunted in MCT1þ/ mice (see Supplementary Figure 1I).
This differential response of MCT2 expression in liver, combined withan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 1631
Brief Communicationthe reduction in hepatic MCT1 expression for MCT1þ/ mice, can
explain the hepatic metabolic shift observed between MCT1þ/þ and
MCTþ/- mice in absence of any change in lactatemia.
Gene expression analysis revealed that HFD feeding was associated with
a shift in the ratio of LDH isoforms, with an increase in LDHB. If LDHA
preferentially converts pyruvate into lactate, the LDHB isoform is asso-
ciated with pyruvate formation from lactate. Thus, these results point to a
possible role of circulating lactate in sustaining hepatic ATP production
by providing pyruvate as an oxidative substrate. This effect is permitted
in MCT1þ/þmice by the increased expression of the MCT2 transporter
while MCT1þ/ mice did not display such an effect (Supplementary
Figure 1I). Moreover, lactate taken up by hepatocytes can be con-
verted to pyruvate that will contribute to the increased neoglucogenesis
observed with the pyruvate tolerance test and thus participate to elevate
glycemia in MCT1þ/þ mice under HFD [30]. MCT1þ/ mice do not
show increased hepatic LDHB isoform expression. Interestingly, LDHB
induction in muscle was recently correlated with a decrease in pH
associated with an increase in intracellular lactate concentration [28].
Thus, an increase in lactate uptake via both MCT1 and MCT2 in hepa-
tocytes with a lowering of intracellular pH could be a trigger for enhanced
LDHB expression as observed in muscle [28]. In our transgenic mouse
model, the reduced hepatic MCT1 transporter expression (as well as the
lack of enhanced MCT2 expression) could prevent the pH/lactate-
dependent induction in LDHB isoform in hepatocytes and the elevated
production of pyruvate. Subsequently, it would lead to a decreased rate
of neoglucogenesis as well as a reduction of the Krebs cycle activity by
providing lower amounts of acetyl-CoA and oxaloacetate via pyruvate
carboxylase. In short, under HFD, oxidative phosphorylation should be
less active in MCT1þ/ mice compared to MCT1þ/þ mice. This is
supported by the lack of enhancement in expression levels of mito-
chondrial complexes in MCT1þ/ mice under HFD compared to
MCT1þ/þ mice. As a consequence, it is postulated that the reduced
hepatic ATP production would increase the AMP/ATP ratio leading to the
increased activation of AMPK. Interestingly, analysis of some signaling
pathways downstream of AMPK show that they are not activated.
Furthermore, the upstream activator of AMPK, LKB1, is not activated
either. Thus, the decreased pyruvate synthesis in MCT1þ/ mice and
the subsequent decrease in ATP production resulting in a rise of the AMP/
ATP ratio is the most likely cause of the active AMPK in MCT1þ/mice.
The consequence of this AMPK activation is the phosphorylation of a
limited and speciﬁc set of downstream targets of AMPK such as ACC.
Phosphorylation of ACC will reduce the production of malonyl-CoA, a
known inhibitor of fatty acid oxidation [29].
AMPK activation was recently shown to phosphorylate at a speciﬁc site
and inhibit SREBP1 [19]. This AMPK-dependent phosphorylation was
demonstrated to protect against hepatic steatosis by inhibiting lipid
metabolism and lipid accumulation. In MCT1þ/þ mice fed HFD, an
increase in the mature, activated form of SREBP1 could be detected.
This is consistent with a low phosphorylation level of SREBP1 at the
AMPK target site. In contrast, MCT1þ/ mice present a decreased
level of the active form of SREBP1. Thus, it appears that activated
AMPK indeed inhibits SREBP1 in MCT1þ/ mice. As a consequence,
several key enzymes of lipid metabolism are not induced by the
exposure to a high fat diet in hepatocytes, leading to a protection
against lipid accumulation and hepatic steatosis in these mice.
5. CONCLUSION
To summarize, the MCT1 haploinsufﬁcient mouse model allowed us to
unravel a key role of lactate metabolism in steatosis onset. In wildtype
mice, the expression of the LDHB isoform is elevated in the liver, most1632 MOLECULAR METABOLISM 6 (2017) 1625e1633  2017 The Authors. Published by Elikely as a consequence of lactate uptake and intracellular acidiﬁcation.
In turn, LDHB leads to elevated pyruvate formation from lactate,
contributing to both neoglucogenesis and enhanced ATP synthesis, the
former by stimulating oxidative phosphorylation. High ATP production
capacity results in a decrease of AMPK phosphorylation (and thus
activity), leading to increased SREBP1 activity that induces different
pathways causing lipid accumulation in the liver. In contrast, in MCT1
haploinsufﬁcient mice, the reduction in lactate uptake caused by lower
MCT1 (and MCT2) expression levels in hepatocytes prevents under
HFD the high LDHB expression and the subsequent cascade. Thus,
pyruvate synthesis is reduced and AMPK becomes more active due to a
reduced ATP production via oxidative phosphorylation. Consequently,
SREBP1 is inhibited, preventing the activation of lipid metabolism and
leading to protection against hepatic steatosis. In conclusion, our re-
sults reinforce the concept that AMPK activation promotes a protection
against hepatic steatosis by inhibiting SREBP1. It also reveals an un-
expected regulatory role of circulating lactate in the regulation of he-
patic lipid metabolism (Supplementary Figure 2). Nonetheless, we do
not exclude that other tissues or organs implicated in the metabolic
dysfunctions associated with obesity, e.g. adipose tissue (which also
express MCT1), could be affected and contribute to the protection
against hepatic steatosis observed in MCT1 haploinsufﬁcient mice.
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